Tirzepatide vs Mounjaro (Manjaro): Clearing Up the Confusion

The misconception worth clearing up first: "manjaro" and "tirzepatide" aren't two competing options

One of the most common questions our prescribers field is some version of: "Should I get tirzepatide or Mounjaro?" It's an easy mix-up. Online searches surface "manjaro" as a variant spelling, and because tirzepatide sounds clinical while Mounjaro sounds branded, people assume they might be different things at different price points. They aren't. Mounjaro is tirzepatide, the same molecule, the same 2.5 mg to 15 mg range, the same KwikPen, the same Eli Lilly supply chain. Once that lands, the real comparison question shifts: tirzepatide versus what?

The answer depends on what you're comparing it to. If you want to understand how it sits against semaglutide (the active ingredient in the other main licensed weight-loss injection in the UK), that's a meaningful clinical discussion. If you've come across references to retatrutide or other pipeline medicines, those are separate molecules at different stages of development. And if you've read about how GLP-1 medicines differ from tirzepatide's dual mechanism, that gets into the pharmacology in useful depth.

What you won't find is a legitimate UK pharmacy selling "tirzepatide" separately from Mounjaro, there is no generic tirzepatide available in the UK. If a seller offers loose tirzepatide or an unlabelled alternative, that's a red flag worth taking seriously.

How tirzepatide actually works, and what the trial data shows

Tirzepatide activates two gut-hormone receptors: GIP and GLP-1. Most weight-loss medicines in the current generation are GLP-1 agonists alone; tirzepatide's dual action is what makes it distinct. Both pathways are involved in appetite signalling and blood-sugar regulation, and activating them together appears to produce a stronger effect on weight than either pathway alone. You can read more about how Mounjaro works in practice and what to expect across the treatment schedule.

In the SURMOUNT-1 trial, which enrolled around 2,500 adults with obesity and ran for 72 weeks, participants on the 15 mg dose saw average body-weight reductions of roughly 20 to 21 percent, a figure NICE cited when recommending tirzepatide in Technology Appraisal TA1026, published in December 2024. In the subsequent SURMOUNT-5 head-to-head, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same 72-week period, as published in the New England Journal of Medicine in 2025. These are average results from clinical trials, individual outcomes vary, and no medicine works the same way for everyone.

The treatment begins at 2.5 mg, a dose chosen because it lets the body adjust rather than because it's therapeutically active at that level. The prescriber guides titration from there, typically in four-week steps, up to a maximum of 15 mg. Missed doses, timing changes and decisions about dose increases are all questions for your prescriber and the Patient Information Leaflet, not something a content page can safely advise on.

Tirzepatide compared to other medicines: a factual summary

The table below sets out the key licensed facts for the main weight-management medicines available in the UK. Numbers are drawn from NICE appraisals and published trial data; they're averages, not predictions for any individual.

Ozempic deserves a specific note: it contains semaglutide, but it is licensed for type 2 diabetes in the UK, not weight management. It is not interchangeable with Wegovy for this purpose, and the NHS medicines page for tirzepatide and its semaglutide equivalent are the right places to read the patient-level detail on each. For anyone curious about how newer molecules in the pipeline compare, retatrutide versus tirzepatide is worth reading alongside a realistic note that retatrutide does not yet have a UK licence.

What actually matters when choosing between licensed options

The trial data gives a useful starting point, and the head-to-head between tirzepatide and semaglutide 2.4 mg is genuine evidence rather than marketing. But average trial figures don't decide which medicine is right for a particular person. Prescribers weigh up your medical history, current medicines, and what your body is likely to tolerate, factors a comparison table can't account for.

Cost is a real consideration for most people. Eli Lilly adjusted Mounjaro's UK list price in September 2025, and private prices now vary noticeably by dose and provider. If you want to understand what drives the pricing, the background to that change is useful reading. At nume, one transparent price covers the consultation, the prescription, the medicine and free next-working-day delivery, the breakdown is on the treatment page.

For a broader look at how tirzepatide sits alongside other emerging treatments, maritide versus tirzepatide covers another pipeline molecule, and reta versus tirzepatide goes into the receptor differences in more detail. These are genuinely evolving areas, worth following if you want to stay informed, but none of them change what's available to prescribe in the UK today. Which licensed option suits you is a clinical decision, and it's one our prescribers work through with you.